Actively Recruiting
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Led by Children's Hospital Medical Center, Cincinnati · Updated on 2025-08-12
190
Participants Needed
3
Research Sites
227 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.
CONDITIONS
Official Title
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 18 years of age or older
- Be scheduled for allogeneic stem cell transplant
- Have a vitamin A level below the upper limit of normal for age
- Be able to tolerate oral vitamin A dose
- Have total bilirubin level less than 1.5 times upper limit of normal
- Have AST and/or ALT less than 3 times upper limit of normal for age
- Receiving peripheral blood stem cells as graft
You will not qualify if you...
- Ongoing raised intracranial pressure
- Liver cirrhosis
- Currently pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
2
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States, 14203
Actively Recruiting
3
The Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
Research Team
C
Celeste Dourson, MS, CCRP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here